Towards Healthcare
Transcriptomics Technologies Market Soars USD 12.79 Billion by 2034

Transcriptomics Technologies Market Growth with Opportunities and Segment Analysis

Market insights predict, the transcriptomics technologies industry is expected to grow from USD 7.01 billion in 2024 to USD 12.79 billion by 2034, driven by a CAGR of 6.24%. The transcriptomics technologies market is growing rapidly because of the growing focus on the development of omics-based therapeutics. North America is leading the market because of its focus on advancing in molecular biology-based healthcare services.

Content

  • Insight Code: 5769
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The transcriptomics technology market is projected to grow from USD 7.44 billion in 2025 to USD 12.79 billion by 2034 at a 6.24% CAGR, signaling robust long-term investment potential.

Next-generation sequencing (NGS) and single-cell RNA sequencing are leading disruptions, enabling faster, cheaper, and more precise analysis.

Trends include the rise of AI-integrated transcriptomic platforms, cloud-based data analytics, precision oncology, and single-cell technology advancements.

AI enhances transcriptomic analysis by offering scalable, automated insights into gene expression patterns, predicting drug response, and identifying biomarkers.

High costs of sequencing platforms and complex data analysis requirements remain key challenges

The market is highly competitive, dominated by players like Illumina, Thermo Fisher, QIAGEN, and 10x Genomics

North America leads due to robust funding, R&D infrastructure, and major biotech players.
Any Questions